Captor Therapeutics Spolka Akcyjna (WSE: CTX)

Market Cap	240.60M
Revenue (ttm)	19.36M
Net Income (ttm)	-41.15M
Shares Out	4.66M
EPS (ttm)	-8.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,392
Open	51.20
Previous Close	51.00
Day's Range	51.00 - 57.40
52-Week Range	49.60 - 109.50
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 105
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2023, CTX's revenue was 13.20 million, an increase of 44.15% compared to the previous year's 9.16 million. Losses were -70.58 million, 96.6% more than in 2022.